

Professor George D. Birkmayer, M.D., Ph.D.

Curriculum and International Relations

Born 1941 Jan 30, Vienna, Austria
Son of Professor Walther Birkmayer, MD (discoverer of the L-DOPA therapy for Parkinson's disease)
1968 Ph.D. in Biochemistry, University of Vienna, Austria
1970-1973 Post Doc Fellow, Dept. of Cell Biology, University Munich
1973 Associate Professor for Cell Biology, University of Munich
1974 Research Fellow with Prof. Bishop, Dept. Microbiology, UCSF (USA)
1976 Guest Lectures at Universities in New York, Philadelphia, Montreal
1979 MD from the University of Munich
1988 Professor for Medical Chemistry, University of Graz, Austria
1983-present: Medical & scientific director, Prof. Birkmayer Laboratories, Vienna, Austria.
1989. Visiting Professor at the University of Beijing (China)
1984-2005: Secretary General of the Int. Academy of Tumor Marker Oncology
1992-present: Chairman & CEO, Menuco Corp. USA
1996-present Visiting Professor at the University of Guangzhou (China)
2000 Fellow of the American College of Nutrition
2003: Visiting Professor at the University of Xi'an (China)
2005: President of the Int. Academy of Tumor Marker Oncology (IATMO)

Professor George Birkmayer, M.D., Ph.D., developer of stabilized NADH, was the first to identify the importance of NADH in cellular development and energy transmissions for all bodily functions and organs. He founded Menuco Corporation in 1995 and is a world-renowned biochemical researcher and Medical Director of the Birkmayer Institute for Parkinson's Therapy, which has treated thousands of patients suffering from Parkinson's disease after having studied the biochemical connections between Parkinsons and NADH .

Professor at the University of Graz, Austria and head of its Division of Neurochemistry at the Department of Medical Chemistry. He is also visiting professor at the University of Beijing and Canton, China and Director of the International Academy of Tumor Marker Oncology in New York . He is the European Editor of the Journal of Tumour Marker Oncology, and a member of the editorial board of the Journal of Experimental and Clinical Cancer Research as well as additional scientific journals. He is a member of several international scientific societies including the New Academy of Sciences and the American Association of Cancer Research. He is also a Fellow of the American College of Nutrition.

Cooperation with Universities and scientific institutions (A)

Georgetown Univ. Washington (USA)
Cornell Univ. New York (USA)
Free University Berlin (Germany)
University Freiburg (Germany)
Max Planck Institute Cologne, Köln (D)
Lomonossow University (Russia)

Cooperation with Universities and scientific institutions (B)

Nagahama Institute (Japan)

University Beijing (China)

University Gunagzhou (China)

University Xian (China)

University Turku (Finland)

University Graz (Austria)

Cooperation with the industry

Merck - (Germany)

Numico Corp. (Netherlands)

Oriental Yeast Corp (Japan)

TP-TUMAPHARMA (Malta)

Westward Pharma (USA)